471.14
-2.15 (-0.45%)
| Penutupan Terdahulu | 473.29 |
| Buka | 472.67 |
| Jumlah Dagangan | 399,550 |
| Purata Dagangan (3B) | 1,096,587 |
| Modal Pasaran | 62,244,106,240 |
| Harga / Pendapatan (P/E TTM) | 1,682.64 |
| Harga / Pendapatan (P/E Ke hadapan) | 53.48 |
| Harga / Jualan (P/S) | 19.59 |
| Harga / Buku (P/B) | 267.34 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Keuntungan | -11.49% |
| Margin Operasi (TTM) | 3.04% |
| EPS Cair (TTM) | -2.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2,358.25% |
| Nisbah Semasa (MRQ) | 3.04 |
| Aliran Tunai Operasi (OCF TTM) | -45.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 223.09 M |
| Pulangan Atas Aset (ROA TTM) | -1.79% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Alnylam Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.00 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 3.81% |
| % Dimiliki oleh Institusi | 97.56% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 570.00 (HC Wainwright & Co., 20.98%) | Beli |
| Median | 507.53 (7.72%) | |
| Rendah | 470.00 (BMO Capital, -0.24%) | Beli |
| Purata | 511.65 (8.60%) | |
| Jumlah | 12 Beli, 2 Pegang | |
| Harga Purata @ Panggilan | 458.20 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 11 Nov 2025 | 479.00 (1.67%) | Pegang | 451.95 |
| Barclays | 31 Oct 2025 | 527.00 (11.86%) | Beli | 456.04 |
| Piper Sandler | 31 Oct 2025 | 489.00 (3.79%) | Beli | 456.04 |
| Jefferies | 30 Oct 2025 | 549.00 (16.53%) | Beli | 449.56 |
| Truist Securities | 17 Oct 2025 | 535.00 (13.55%) | Beli | 481.67 |
| JP Morgan | 13 Oct 2025 | 473.00 (0.39%) | Beli | 464.95 |
| HC Wainwright & Co. | 10 Oct 2025 | 570.00 (20.98%) | Beli | 460.46 |
| Morgan Stanley | 06 Oct 2025 | 475.00 (0.82%) | Pegang | 452.00 |
| Stifel | 06 Oct 2025 | 495.00 (5.06%) | Beli | 452.00 |
| RBC Capital | 19 Sep 2025 | 500.00 (6.13%) | Beli | 453.56 |
| B of A Securities | 17 Sep 2025 | 520.00 (10.37%) | Beli | 451.73 |
| Goldman Sachs | 16 Sep 2025 | 566.00 (20.13%) | Beli | 461.24 |
| Evercore ISI Group | 11 Sep 2025 | 515.05 (9.32%) | Beli | 468.58 |
| BMO Capital | 08 Sep 2025 | 470.00 (-0.24%) | Beli | 455.03 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| GREENSTREET YVONNE | - | 445.12 | -1,121 | -498,980 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,121 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -498,980 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 445.12 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| GREENSTREET YVONNE | Pegawai | 26 Nov 2025 | Dibuang (-) | 1,121 | 445.12 | 498,980 |
| GREENSTREET YVONNE | Pegawai | 26 Nov 2025 | Pelaksanaan pilihan | 4,697 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |